Patient demographics, infections, and causes of death among recipients of CAR T cells for treatment of hematologic malignancies who subsequently developed grade 1 CRS, with or without tocilizumab therapy
| Characteristic . | No tocilizumab for CRS . | Tocilizumab for CRS . | P* . |
|---|---|---|---|
| Patients, n | 225 | 166 | |
| Age at infusion ≥65 y | 67 (29.8) | 58 (34.9) | |
| Males | 153 (68) | 112 (67.5) | |
| Karnofsky performance score prior to treatment 90-100% | 109 (48.4) | 66 (39.8) | |
| Neurotoxicity/ICANS of any stage | 92 (40.9) | 100 (60.2) | <.001 |
| Corticosteroids for ICANS or CRS | 39 (17.3) | 88 (53) | <.001 |
| Infections† | |||
| Clinically significant infections within 100 d | 67 (29.8) | 52 (31.3) | .85 |
| Bacterial | 38 (16.9) | 37 (22.3) | |
| Fungal | 6 (2.7) | 7 (4.2) | |
| Yeast | 4 (1.8) | 5 (3) | |
| Mold | 3 (1.3) | 2 (1.2) | |
| Viral‡ | 32 (14.2) | 19 (11.4) | |
| Respiratory virus | 22 (9.8) | 8 (4.8) | |
| Herpes family virus | 6 (2.7) | 12 (7.2) | |
| GI/liver | 4 (1.8) | 0 | |
| GU | 4 (1.8) | 4 (2.4) | |
| Other viral infections | 2 (0.9) | 0 | |
| Other | 1 (0.4) | 0 |
| Characteristic . | No tocilizumab for CRS . | Tocilizumab for CRS . | P* . |
|---|---|---|---|
| Patients, n | 225 | 166 | |
| Age at infusion ≥65 y | 67 (29.8) | 58 (34.9) | |
| Males | 153 (68) | 112 (67.5) | |
| Karnofsky performance score prior to treatment 90-100% | 109 (48.4) | 66 (39.8) | |
| Neurotoxicity/ICANS of any stage | 92 (40.9) | 100 (60.2) | <.001 |
| Corticosteroids for ICANS or CRS | 39 (17.3) | 88 (53) | <.001 |
| Infections† | |||
| Clinically significant infections within 100 d | 67 (29.8) | 52 (31.3) | .85 |
| Bacterial | 38 (16.9) | 37 (22.3) | |
| Fungal | 6 (2.7) | 7 (4.2) | |
| Yeast | 4 (1.8) | 5 (3) | |
| Mold | 3 (1.3) | 2 (1.2) | |
| Viral‡ | 32 (14.2) | 19 (11.4) | |
| Respiratory virus | 22 (9.8) | 8 (4.8) | |
| Herpes family virus | 6 (2.7) | 12 (7.2) | |
| GI/liver | 4 (1.8) | 0 | |
| GU | 4 (1.8) | 4 (2.4) | |
| Other viral infections | 2 (0.9) | 0 | |
| Other | 1 (0.4) | 0 |
Unless otherwise noted, data are n (%).
GI, gastrointestinal; GU, genitourinary.
Pearson χ2 test.
Number of patient-reported infections. Types of infections are not mutually exclusive; several infections may occur in each patient.
Respiratory virus: coronavirus excluding SARS-CoV-2, influenza A and B, metapneumovirus, parainfluenza, respiratory syncytial virus, and rhinovirus. Herpes family virus: cytomegalovirus, Epstein-Barr virus, herpes simplex virus, and human herpesvirus-6. GI/liver: hepatitis A and B and enterovirus. GU: BK polyomavirus. Other viral infections: parvovirus B-19.